News Sentiment

AARD sentiment intelligence

Aardvark Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 47 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.60 Week of 10 Jul 2026
Weighted tone 47/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+33.3% over one week, +94.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Aardvark Therapeutics(AARD) Stock Options Chain | Quotes & News

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 33.3% Price confirming higher
Trend fit Trend inactive 94.9% over four weeks
Fair value -22.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 39
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
TradingView 9
Market source 8
simplywall.st 5
Stocktwits 4
www.marketscreener.com 4
Stock Titan 3
TradingKey 3
MT Newswires 3

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 17
Analyst action 7
Regulatory and legal 4
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Stock Titan Direct company coverage

[DEF 14A] Aardvark Therapeutics, Inc. Definitive Proxy Statement

Aardvark Therapeutics, Inc. is holding a virtual annual stockholders' meeting on August 14, 2026, to vote on three proposals including the election of two Class I directors, ratification of BDO USA, P.C. as auditor, and a significant repricing of underwater employee stock options

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 19:39
Source
Stock Titan
Quartr Direct company coverage

Aardvark Therapeutics (AARD) Cantor Global Healthcare Conference 2025 Summary

This summary of Aardvark Therapeutics' (AARD) Cantor Global Healthcare Conference 2025 presentation details their focus on gut-restricted, oral small molecule drugs for hunger and appetite, particularly for Prader-Willi syndrome and obesity. The company highlighted promising prec

Tone
Positive 66/100
Event
Market update
Published
08 Jul 2026 11:40
Source
Quartr
Stock Titan Direct company coverage

Aardvark Therapeutics (NASDAQ: AARD) asks shareholders to reprice 2.8M options

Aardvark Therapeutics is seeking shareholder approval to reprice approximately 2.8 million outstanding stock options, representing about 13% of its issued share capital. This move aims to retain and motivate employees whose options are currently "underwater" due to a significant

Tone
Negative 34/100
Event
Regulatory and legal
Published
29 Jun 2026 20:09
Source
Stock Titan
www.marketscreener.com Direct company coverage

Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 2000 Dynamic Index

Aardvark Therapeutics, Inc. (NasdaqGS:AARD) has been removed from several Russell indices, including the Russell 2000 Dynamic Index, Russell 3000E Index, Russell Small Cap Completeness Index, Russell 2500 Index, and Russell 3000 Index. This follows recent news from May where the

Tone
Negative 31/100
Event
Market update
Published
29 Jun 2026 17:33
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 3000E Index

Aardvark Therapeutics, Inc. (NasdaqGS: AARD) has been removed from the Russell 3000E Index, among several other Russell indices, on June 29, 2026. The company, a clinical-stage biopharmaceutical firm, is focused on developing therapies for metabolic diseases, with its lead produc

Tone
Negative 32/100
Event
Market update
Published
29 Jun 2026 14:02
Source
www.marketscreener.com
TradingView Direct company coverage

Price to earnings forward of Aardvark Therapeutics, Inc. – NASDAQ:AARD

The article focuses on the "Price to earnings forward" metric for Aardvark Therapeutics, Inc. (NASDAQ: AARD). It briefly presents this financial data point within the context of the company's profile on TradingView. The page primarily shows navigation and disclaimer information,

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 10:39
Source
TradingView
PR Newswire Direct company coverage

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS

Hagens Berman has initiated an investigation into Aardvark Therapeutics (NASDAQ: AARD) after its stock price dropped 56% following the company's announcement to pause its Phase 3 HERO trial for ARD-101 due to serious safety concerns, specifically "reversible cardiac observations.

Tone
Negative 28/100
Event
Regulatory and legal
Published
29 Jun 2026 10:39
Source
PR Newswire
www.marketscreener.com Direct company coverage

Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell 3000 Value Benchmark

Aardvark Therapeutics, Inc. (NasdaqGS:AARD) has been removed from the Russell 3000 Value Benchmark. This decision follows a series of recent events, including a significant drop in share price due to an FDA clinical hold on its lead drug candidate, ARD-101, and subsequent analyst

Tone
Negative 14/100
Event
Analyst action
Published
29 Jun 2026 04:40
Source
www.marketscreener.com
Stocktwits Direct company coverage

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial

Aardvark Therapeutics (AARD) shares plunged 54% pre-market after the company voluntarily paused its HERO Phase 3 trial due to reversible cardiac effects found in a healthy volunteer. This unexpected development led to multiple brokerage downgrades, with analysts expressing signif

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 03:41
Source
Stocktwits
www.marketscreener.com Direct company coverage

Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell 2500 Value Benchmark

Aardvark Therapeutics, Inc. (NasdaqGS:AARD) has been removed from the Russell 2500 Value Benchmark, according to an announcement published on June 28, 2026, by S&P Capital IQ. This follows its removal from several other Russell indices on June 29, 2026, including the Russell 2000

Tone
Negative 29/100
Event
Market update
Published
28 Jun 2026 21:13
Source
www.marketscreener.com
TradingView Direct company coverage

Aardvark Therapeutics, Inc. Actuals & Estimates (BOATS:AARD)

This article provides an overview of Aardvark Therapeutics, Inc. (BOATS:AARD) stock, including financial actuals, analyst estimates, historical price data, and upcoming earnings information. It highlights key financial metrics, earnings surprises, revenue details, and confirms th

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 07:10
Source
TradingView
TradingView Direct company coverage

Aardvark Therapeutics, Inc. Actuals & Estimates (NASDAQ:AARD)

This article provides an overview of Aardvark Therapeutics, Inc. (NASDAQ: AARD) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's financial estimates, past earnings reports, upcoming earnings da

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 16:10
Source
TradingView
TradingView Direct company coverage

AARD Forecast — Price Target — Prediction for 2027

This article provides a forecast for Aardvark Therapeutics, Inc. (AARD) stock, including current price, analyst ratings, price targets, and historical performance. It details financial metrics such as earnings per share and revenue, upcoming earnings dates, market capitalization,

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Aardvark Therapeutics, Inc. – NASDAQ:AARD

This article provides financial data for Aardvark Therapeutics, Inc. (NASDAQ: AARD), specifically focusing on its forward price-to-sales ratio. The content is sourced from TradingView, which offers various financial tools and market data services. It includes an overview of the c

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 23:10
Source
TradingView
Bitget Direct company coverage

The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gai

The Nasdaq Biotechnology Index experienced a rise of over 1.52%. Absci, Silence Therapeutics, Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies were among the constituents that saw significant gains. Conversely, Abivax ADR, Quan

Tone
Positive 72/100
Event
Market update
Published
24 Jun 2026 21:40
Source
Bitget
TradingKey Direct company coverage

Aardvark Therapeutics Inc (AARD) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides historical dividend and stock split information for Aardvark Therapeutics Inc (AARD). It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split history. Financial data shows AARD with a market cap

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 06:40
Source
TradingKey
TradingKey Direct company coverage

Aardvark Therapeutics Inc (AARD) Institutional Confidence

This article provides details on the institutional confidence score for Aardvark Therapeutics Inc (AARD), including its current stock price and market capitalization. It lists key institutional shareholders and their shareholdings, noting changes in their positions. The informati

Tone
Positive 60/100
Event
Market update
Published
17 Jun 2026 17:39
Source
TradingKey
TradingKey Direct company coverage

Aardvark Therapeutics Inc (AARD) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Aardvark Therapeutics Inc (AARD), detailing its current stock price, market capitalization, and various valuation metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these metrics have not yet been disclosed by the

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 17:39
Source
TradingKey
Stock Titan Direct company coverage

Executive retention bonuses outlined at Aardvark Therapeutics (NASDAQ: AARD)

Aardvark Therapeutics (NASDAQ: AARD) has approved cash retention bonuses for two senior executives: CFO and COO Nelson Sun, and CMO Manasi Jaiman, M.D., M.P.H. Sun is eligible for a total of $346,500 and Jaiman for $357,000, with both packages comprising a guaranteed annual bonus

Tone
Neutral 50/100
Event
Balance sheet
Published
12 Jun 2026 19:38
Source
Stock Titan
PR Newswire Direct company coverage

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

Pomerantz LLP is investigating Aardvark Therapeutics, Inc. (AARD) on behalf of investors for potential securities fraud and unlawful business practices. This investigation follows a significant drop in Aardvark's stock price after the company voluntarily paused its Phase 3 HERO t

Tone
Negative 15/100
Event
Regulatory and legal
Published
11 Jun 2026 14:10
Source
PR Newswire
Sahm Direct company coverage

Aardvark Therapeutics Insiders Lose Out As Stock Sinks To US$3.59

Insiders of Aardvark Therapeutics, Inc. who purchased US$450.3k worth of stock at an average price of US$9.79 over the last year have seen their investment decline to US$165.1k due to a recent 10% stock decrease to US$3.59. Despite the losses, insiders, including CEO Tien-Li Lee,

Tone
Negative 35/100
Event
Market update
Published
09 Jun 2026 14:09
Source
Sahm
GlobeNewswire Direct company coverage

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid

Hagens Berman has initiated an investigation into Aardvark Therapeutics (AARD) after the company's shares dropped 56% following the pause of its Phase 3 HERO trial for ARD-101. The pause was due to "reversible cardiac observations," raising concerns about the accuracy of Aardvark

Tone
Negative 5/100
Event
Regulatory and legal
Published
03 Jun 2026 02:09
Source
GlobeNewswire